The role of inflammation in atherothrombosis: Implications for clinical practice

Vascular Medicine

Volumn 10, Issue 1, 2005, Pages 45-53

  Tedgui, Alain ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cytokines; Immunology; Inflammation; Molecular risk factors; Plaque rupture; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CLOPIDOGREL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; METALLOPROTEINASE; N(G),N(G) DIMETHYLARGININE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORRELATION FUNCTION; DISEASE MARKER; DRUG EFFICACY; HUMAN; INFLAMMATION; MEDIATOR; PATHOGENESIS; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOGENESIS; THROMBOSIS;

ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULES; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METALLOPROTEASES; THROMBOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18744362524     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm589ra     Document Type: Review

References (92)

1. Yusuf S, Ounpuu S, Anand S. The global epidemic of atherosclerotic cardiovascular disease. Med Princ Pract 2002; 11 (suppl 2): 3-8.
2. Bonow RO, Smaha LA, Smith SC Jr et al. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002; 106: 1602-605.
3. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-43.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
5. Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13 (suppl 1): 7-11.
6. Buffon A, Biasucci LM, Liuzzo G et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
7. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
8. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503-16.
9. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91 (3A): 3A-6A.
10. Lutgens E, van Suylen RJ, Faber BC et al. Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol 2003; 23: 2123-30.
11. Virmani R, Burke AP, Farb A et al. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002; 44: 349-56.
12. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci 2001; 947: 167-79; discussion: 179-80.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
14. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-62.
15. Kolodgie FD, Narula J, Burke AP et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 2000; 157: 1259-68.
16. Hutter R, Valdiviezo C, Sauter BV et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 2004; 109: 2001-2008.
17. Ruberg FL, Leopold JA, Loscalzo J. Atherothrombosis: plaque instability and thrombogenesis. Prog Cardiovasc Dis 2002; 44: 381-94.
18. Chyu KY, Shah PK. The role of inflammation in plaque disruption and thrombosis. Rev Cardiovasc Med 2001; 2: 82-91.
19. Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep 2004; 6: 243-50.
20. Holvoet P. Oxidative modification of low-density lipoproteins in atherothrombosis. Acta Cardiol 1998; 53: 253-60.
21. Vaarala O. Antibodies to oxidized LDL. Lupus 2000; 9: 202-205.
22. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-87.
23. Libby P, Sukhova G, Lee RT et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25 (suppl 2): S9-12.
24. Nelken NA, Coughlin SR, Gordon D et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-27.
25. Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic disease. Best Pract Res Clin Rheumatol 2004; 18: 31-45.
26. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
27. Mallat Z, Gojova A, Marchiol-Fournigault C et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930-34.
28. Kapadia S, Dibbs Z, Kurrelmeyer K et al. The role of cytokines in the failing human heart. Cardiol Clin 1998; 16: 645-56.
29. Castellanos M, Castillo J, Garcia MM et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002; 33: 982-87.
30. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990; 7: 147-59.
31. Seino Y, Ikeda U, Ikeda M et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6: 87-91.
32. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85-97.
33. Blan AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-54.
34. Etter H, Althaus R, Eugster HP, Santamaria-Babi LF, Weber L, Moser R. IL-4 and IL- 13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression. Cytokine 1998; 10: 395-403.
35. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-35.
36. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-29.
37. Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis 2003; 14: 65-79.
38. Henn V, Steinbach S, Buchner K et al. The inflammatory action of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by co-expressed CD40. Blood 2001; 98: 1047-54.
39. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32.
40. Schonbeck U, Sukhova GK, Shimizu K et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000; 97: 7458-63.
41. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
42. Xu XP, Meisel SR, Ong JM et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-98.
43. Pasterkamp G, Galis ZS, de Kleijn DP. Expansive arterial remodeling: location, location, location. Arterioscler Thromb Vasc Biol 2004; 24: 650-57.
44. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
45. Jialal L, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
46. Saigo M, Waters DD, Abe S et al. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction.
47. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-95.
48. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87: 9383-87.
49. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 1998; 9: 441-48.
50. Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. Presented at the 71st scientific sessions of the American Heart Association. Dallas, Texas. Circulation 1999; 99: 1132-37.
51. Badimon JJ, Lettino M, Toschi V et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-87.
52. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004; 97: 673-78.
53. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-79.
54. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
55. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
56. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
57. Ridker PM, Rifai N, Pfeffer M et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
58. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-71.
59. Ridker PM, Cushman M, Stampfer MJ et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-28.
60. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47.
61. Chew DP, Bhatt DL, Robbins MA et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992-97.
62. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-65.
63. Pearson TA, Mensah GA, Alexander RW et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
64. Danesh J, Phil D, Wheeler J et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
65. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999; 54: M357-64.
66. Haught WH, Mansour M, Rothlein R et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996; 132: 1-8.
67. Schönbeck U, Varo N, Libby P et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-68.
68. Blake GJ, Ostfeld RJ, Yucel EK et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003; 23: e11-e14.
69. Danesh J, Collins R, Appleby P et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
70. Yarnell JW, Baker IA, Sweetnam PM et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
71. Zoccali C, Benedetto FA, Maas R et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-96.
72. Valkonen VP, Päivä H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-28.
73. Pratico D, Iuliano L, Mauriello A et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-34.
74. Mallat Z, Nakamura T, Ohan J et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999; 103: 421-27.
75. Kaikita K, Ogawa H, Yasue H et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997; 17: 2232-37.
76. Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96: 2311-15.
77. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-68.
78. Scholkens BA, Landgraf W. ACE inhibition and atherogenesis. Can J Physiol Pharmacol 2002; 80: 354-59.
79. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-93.
80. Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-99.
81. Koh KK, Son JW, Ahn JY et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: e19-23.
82. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-57.
83. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
84. Hermann A, Rauch BH, Braun M et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
85. Klinkhardt U, Bauersachs R, Adams J et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-41.
86. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-8.
87. Cha JK, Jeong MH, Lee KM et al. Changes in platelet p-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002; 14: 145-50.
88. Vivekananathan DP, Bhatt DL, Chew DP et al. Effect of clopidogrel pretreatment on periprocedural rise of C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004 Aug 1; 94: 358-60.
89. Dunzendorfer S, Reinisch CM, Kaneider NC et al. Inhibition of plasma-dependent monocyte chemokinesis and cytokine-triggered endothelial activation for neutrophil transmigration by administration of clopidogrel in man. Acta Med Austriaca 2002; 29: 100-106.
90. Quinn MJ, Bhatt DL, Zidar F, Vivekananathan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-84.
91. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effects of statin therapy on LDL cholesterol, C-reactive protein, and the progression of coronary artery disease. N Engl J Med 2005; 352: 29-38.
92. Ridker PM, Cannon CP, Morrow D et al. Clinical relevance of C-reactive protein levels after statin therapy. N Engl J Med 2005; 352: 20-28.